GlassScriptPhysician profile
Callie Tuggle
NPI 1902295983
$3,533.00
in general payments reported to CMS, 2019-2025
28 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.06 · 2022: $705 · 2023: $654 · 2024: $1,067 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,813.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $753.67 | 2022-2025 | |
| Novo Nordisk INC | $671.00 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $264.12 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Corcept Therapeutics | $219.14 | 2024-2025 | Korlym |
| Antares Pharma, INC. | $207.93 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.23 | 2022-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $164.07 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $140.82 | 2022-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $136.03 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $99.28 | 2023-2025 | Gvoke Hypopen |
| Pfizer INC. | $96.90 | 2023-2025 | |
| Astellas Pharma US INC | $84.03 | 2023-2024 | Veozah |
| Glaxosmithkline, LLC. | $73.36 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $57.57 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.10 | 2024-2025 | Caplyta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $48.89 | 2023-2024 | Freestyle Libre 2 |
| Hologic Sales and Service, LLC | $43.11 | 2022-2024 | Aptima |
| Phathom Pharmaceuticals, INC. | $34.15 | 2025 | Voquezna |
| Inspire Medical Systems, INC. | $33.04 | 2025 | Inspire |
| Shield Therapeutics INC | $30.72 | 2022-2023 | Accrufer |
| Nevro Corp. | $25.08 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.65 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $18.34 | 2022 | |
| Halozyme INC | $18.07 | 2023 | |
| Alexion Pharmaceuticals, INC. | $15.59 | 2023 | Strensiq |
| Horizon Therapeutics Plc | $14.88 | 2023 | Krystexxa |
| Daiichi Sankyo INC. | $14.06 | 2021 | |
| Tolmar, INC. | $13.17 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Callie Tuggle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.